IHP-102
Acute vaso-occlusive crisis in sickle cell disease
Pre-clinicalActive
Key Facts
Indication
Acute vaso-occlusive crisis in sickle cell disease
Phase
Pre-clinical
Status
Active
Company
About IHP Therapeutics
IHP Therapeutics is a private, pre-revenue biotech founded in 2018 and headquartered in San Carlos, California. The company is singularly focused on advancing IHP-102, a novel dual P-selectin and complement inhibitor, as a potential at-home rescue therapeutic for acute pain crises in sickle cell disease (SCD). This approach targets two key drivers of vaso-occlusion and aims to reduce both symptoms and long-term organ damage. With a lean team and expert advisors, IHP is positioning itself to address a significant unmet need by shifting SCD crisis management away from overburdened emergency healthcare systems.
View full company profile